|
1
|
Li CC, Xu B, Hirokawa M, Qian Z, Yoshimoto
K, Horiguchi H, Tashiro T and Sano T: Alterations of E-cadherin,
alpha-catenin and beta-catenin expression in neuroendocrine tumors
of the gastrointestinal tract. Virchows Arch. 440:145–154. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scherübl H, Streller B, Stabenow R, Herbst
H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K
and Zappe SM: Clinically detected gastroenteropancreatic
neuroendocrine tumors are on the rise: Epidemiological changes in
Germany. World J Gastroenterol. 19:9012–9019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: World Health Organization Classification of Tumours of
the Digestive System. 3. 4th. IARC Press; Lyon: 2010
|
|
5
|
Shebani KO, Souba WW, Finkelstein DM,
Stark PC, Elgadi KM, Tanabe KK and Ott MJ: Prognosis and survival
in patients with gastrointestinal tract carcinoid tumors. Ann Surg.
229:815–821. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buitrago D, Trencheva K, Zarnegar R,
Finnerty B, Aldailami H, Lee SW, Sonoda T, Milsom JW and Fahey TJ
III: The impact of incidental identification on the stage at
presentation of lower gastrointestinal carcinoids. J Am Coll Surg.
213:652–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Federspiel BH, Hansen CP, Vainer B,
Hasselby JP, Bardram L and Knigge U: Incidence, pathology and
clinical course and symptoms of neuroendocrine gastrointestinal
tumours. Ugeskr Laeger. 172:2946–2950. 2010.(In Danish). PubMed/NCBI
|
|
8
|
Lawrence B, Gustafsson BI, Chan A, Svejda
B, Kidd M and Modlin IM: The epidemiology of gastroenteropancreatic
neuroendocrine tumors. Endocrinol Metab Clin North Am. 40:1–18.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salyers WJ, Vega KJ, Munoz JC, Trotman BW
and Tanev SS: Neuroendocrine tumors of the gastrointestinal tract:
Case reports and literature review. World J Gastrointest Oncol.
6:301–310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maggard MA, O'Connell JB and Ko CY:
Updated population-based review of carcinoid tumors. Ann Surg.
240:117–122. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garcia-Carbonero R, Capdevila J,
Crespo-Herrero G, DíazPérez JA, Martínez Del Prado MP, Alonso
Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez
A, Llanos-Muñoz M, et al: Incidence, patterns of care and
prognostic factors for outcome of gastroenteropancreatic
neuroendocrine tumors (GEP-NETs): Results from the National Cancer
Registry of Spain (RGETNE). Ann Oncol. 21:1794–1803. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oberndorfer S: Carcinoid tumors of the
duodenum. Frankfurter Zeitschrift für Pathologie. 1:426–432.
1907.(In German).
|
|
13
|
Williams ED and Sandler M: The
classification of carcinoid tumours. Lancet. 1:238–239. 1963.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirabayashi K, Zamboni G, Nishi T, Tanaka
A, Kajiwara H and Nakamura N: Histopathology of gastrointestinal
neuroendocrine neoplasms. Front Oncol. 3:22013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weinstock B, Ward SC, Harpaz N, Warner RR,
Itzkowitz S and Kim MK: Clinical and prognostic features of rectal
neuroendocrine tumors. Neuroendocrinology. 98:180–187. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landry CS, Brock G, Scoggins CR, McMasters
KM and Martin RC II: Proposed staging system for colon carcinoid
tumors based on an analysis of 2,459 patients. J Am Coll Surg.
207:874–881. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Medrano-Guzmán R, Alvarado-Cabrero I,
González-Rodríguez D, López-García SC and Páez-Agraz F: Surgical
prognostic factors of gastroenteropancreatic neuroendocrine tumors
(GEP NET). Rev Med Inst Mex Seguro Soc. 50:243–248. 2012.(In
Spanish). PubMed/NCBI
|
|
18
|
Lim T, Lee J, Kim JJ, Lee JK, Lee KT, Kim
YH, Kim KW, Kim S, Sohn TS, Choi DW, et al: Gastroenteropancreatic
neuroendocrine tumors: Incidence and treatment outcome in a single
institution in Korea. Asia Pac J Clin Oncol. 7:293–299. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curran T, Tulin-Silver S, Patel K, Ward S,
Schneiderman M, Harpaz N, Schwartz M, Itzkowitz S, Warner RR and
Kim MK: Prognostic clinicopathologic factors in longitudinally
followed patients with metastatic small bowel carcinoid tumors.
Pancreas. 40:1253–1257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH,
Hwang TL, Rau KM, Yeh KY, Chen TC and Sun CF: Chromogranin A is a
reliable biomarker for gastroenteropancreatic neuroendocrine tumors
in an Asian population of patients. Neuroendocrinology. 95:344–350.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou WC, Chen JS, Hung YS, Hsu JT, Chen
TC, Sun CF, Lu CH and Hwang TL: Plasma chromogranin A levels
predict survival and tumor response in patients with advanced
gastroenteropancreatic neuroendocrine tumors. Anticancer Res.
34:5661–5669. 2014.PubMed/NCBI
|
|
22
|
Knigge U and Hansen CP: Surgery for
GEP-NETs. Best Pract Res Clin Gastroenterol. 26:819–831. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fendrich V and Bartsch DK: Surgical
treatment of gastrointestinal neuroendocrine tumors. Langenbecks
Arch Surg. 396:299–311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang LC, Poultsides GA and Norton JA:
Surgical management of neuroendocrine tumors of the
gastrointestinal tract. Oncology (Williston Park). 25:794–803.
2011.PubMed/NCBI
|
|
25
|
Ohtsuka T, Takahata S, Ueda J, Ueki T,
Nagai E, Mizumoto K, Shimizu S and Tanaka M: Surgical treatment of
gastroentero-pancreatic neuroendocrine tumor. Gan To Kagaku Ryoho.
40:843–846. 2013.(In Japanese). PubMed/NCBI
|
|
26
|
Gaujoux S, Sauvanet A and Belghiti J:
Place of surgical resection in the treatment strategy of
gastrointestinal neuroendocrine tumors. Target Oncol. 7:153–159.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scherübl H, Jensen RT, Cadiot G, Stölzel U
and Klöppel G: Management of early gastrointestinal neuroendocrine
neoplasms. World J Gastrointest Endosc. 3:133–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pavel ME, Hainsworth JD, Baudin E, Peeters
M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM,
et al: RADIANT-2 Study Group: Everolimus plus octreotide
long-acting repeatable for the treatment of advanced neuroendocrine
tumours associated with carcinoid syndrome (RADIANT-2): A
randomised, placebo-controlled, phase 3 study. Lancet.
378:2005–2012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reidy DL, Tang LH and Saltz LB: Treatment
of advanced disease in patients with well-differentiated
neuroendocrine tumors. Nat Clin Pract Oncol. 6:143–152. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khasraw M, Yap SY and Ananda S:
Neuroendocrine neoplasms of the GI tract: The role of cytotoxic
chemotherapy. Expert Rev Anticancer Ther. 13:451–459. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Castellano D, Bajetta E, Panneerselvam A,
Saletan S, Kocha W, O'Dorisio T, Anthony LB and Hobday T: RADIANT-2
Study Group: Everolimus plus octreotide long-acting repeatable in
patients with colorectal neuroendocrine tumors: A subgroup analysis
of the phase III RADIANT-2 study. Oncologist. 18:46–53. 2013.
View Article : Google Scholar : PubMed/NCBI
|
